<DOC>
	<DOCNO>NCT02776605</DOCNO>
	<brief_summary>Evaluate response ( complete hematologic response [ CHR ] , complete cytogenetic response [ CCyR ] , major molecular response [ MMR ] complete molecular response [ CMR ] combination ponatinib standard chemotherapy ( accord PETHEMA ALL Ph08 trial ) young patient Ph+ ( BCR-ABL ) ALL . All patient treat : Pre-phase ( maximum 7 day , -7 -1 ) : Prednisone 60 mg/m2/day IV 7 day ( -7 -1 ) triple intrathecal therapy ( TIT ) ( Methotrexate [ MTX ] : 12 mg , ARA-C : 30 mg , hydrocortisone : 20 mg ) . 2 . Induction ( day 1 day 28 hematological recovery ) Vincristine ( VCR ) : 1.5 mg/m2 ( maximum 2 mg ) IV day 1 , 8 , 15 22 . Daunorubicin ( DNR ) : 45 mg/m2 IV day 1 , 8 , 15 22 . Prednisone ( PDN ) : 60 mg/m2/day , IV PO , day 1 27 . Ponatinib 30 mg , PO day 1 consolidation . TIT , day 1 22 . 3 . Consolidation ( day 1 day 63 ) Mercaptopurine ( MP ) : 50 mg/m2 , PO day 1 7 , 28 35 56 63 . MTX : 1,5 g/m2 , IV ( 24 h continuous infusion ) day 1 , 28 56 . VP-16 : 100 mg/m2/12 h , IV , day 14 42 . ARA-C : 1000 mg/m2/12 h , IV , day 14-15 42-43 . TIT ( MTX : 12 mg , ARA-C : 30 mg , hydrocortisone : 20 mg ) , , day 1 , 28 56 . Ponatinib 30 mg/d PO , day 1 15 day HSCT . 4 . HSCT ( perform ideally within 1 month end consolidation ) . AlloHSCT prefer autoHSCT ( autoHSCT indicate alloHSCT feasible ) . Myeloablative conditioning cyclophosphamide total body irradiation ( TBI ) whenever possible . 5 . Post HSCT therapy After alloHSCT . Frequent monitoring MRD ( every month ) . I After autoHSCT : Frequent monitoring MRD ( every month ) .</brief_summary>
	<brief_title>Ponatinib With Chemotherapy Young Adults Ph Positive Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>Objectives Primary 1 . To evaluate response ( complete hematologic response [ CHR ] , complete cytogenetic response [ CCyR ] , major molecular response [ MMR ] complete molecular response [ CMR ] combination ponatinib standard chemotherapy ( accord PETHEMA ALL Ph08 trial ) young patient Ph+ ( BCR-ABL ) ALL . 2 . To evaluate event free survival ( EFS ) combination ponatinib standard chemotherapy ( accord PETHEMA ALL Ph08 trial ) young patient Ph+ ( BCR-ABL ) ALL . Secondary - To evaluate rate patient receive allogeneic hematopoietic stem cell transplant ( alloHSCT ) first CR - To evaluate frequency MMR CMR time alloHSCT - To evaluate transplant-related mortality ( TRM ) - To evaluate CR duration overall survival ( OS ) combination ponatinib standard chemotherapy ( accord PETHEMA ALL Ph08 trial ) young patient Ph+ ( BCR-ABL ) ALL . - To evaluate outcome measure ( CR duration , OS EFS ) context observe PETHEMA ALL Ph08 trial . - To observe type number BCR-ABL kinase domain mutation develop study . - To evaluate side effect , adverse event ( AE ) serious AE ( SAE ) . Interventions : 1 . Pre-phase ( maximum 7 day , -7 -1 ) : Prednisone 60 mg/m2/day IV 7 day ( -7 -1 ) triple intrathecal therapy ( TIT ) ( Methotrexate [ MTX ] : 12 mg , ARA-C : 30 mg , hydrocortisone : 20 mg ) . 2 . Induction ( day 1 day 28 hematological recovery ) Vincristine ( VCR ) : 1.5 mg/m2 ( maximum 2 mg ) IV day 1 , 8 , 15 22 . Daunorubicin ( DNR ) : 45 mg/m2 IV day 1 , 8 , 15 22 . Prednisone ( PDN ) : 60 mg/m2/day , IV PO , day 1 27 . Ponatinib 30 mg , PO day 1 consolidation . TIT , day 1 22 . 3 . Consolidation ( day 1 day 63 ) Mercaptopurine ( MP ) : 50 mg/m2 , PO day 1 7 , 28 35 56 63 . MTX : 1,5 g/m2 , IV ( 24 h continuous infusion ) day 1 , 28 56 . VP-16 : 100 mg/m2/12 h , IV , day 14 42 . ARA-C : 1000 mg/m2/12 h , IV , day 14-15 42-43 . TIT ( MTX : 12 mg , ARA-C : 30 mg , hydrocortisone : 20 mg ) , , day 1 , 28 56 . Ponatinib 30 mg/d PO , day 1 15 day HSCT . 4 . HSCT ( perform ideally within 1 month end consolidation ) . AlloHSCT prefer autoHSCT ( autoHSCT indicate alloHSCT feasible ) . Myeloablative conditioning cyclophosphamide total body irradiation ( TBI ) whenever possible . 5 . Post HSCT therapy After alloHSCT . Frequent monitoring MRD ( every month ) . If MRD negative : therapy . If MRD positive , Ponatinib 30 mg/d , po , 2 yr. HSCT . The ponatinib dose reduce 15 mg/d second year patient sustain molecular response . After autoHSCT : Frequent monitoring MRD ( every month ) . All patient receive Ponatinib : 30 mg/d , PO , mercaptopurine , ( 40 mg/m2/d , PO ) methotrexate ( 15 mg/m2/week , IM ) , first year HSCT . The ponatinib dose reduce 15 mg/d second year patient sustain molecular response .</detailed_description>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Ponatinib</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Age 1855 yr. De novo Ph+ ( BCRABL ) ALL ECOG score ≤2 unless due ALL Absence significant liver disease , define follow criterion : total serum bilirubin ≤1.5 x upper limit normal ( ULN ) , unless due Gilbert 's syndrome , alanine aminotransferase ( ALT ) ≤2.5 × ULN ≤5 x ULN leukemic involvement liver present , aspartate aminotransferase ( AST ) ≤2.5 × ULN ≤5 x ULN leukemic involvement liver present . Adequate pancreatic function define serum lipase amylase ≤1.5 × ULN . No history dyslipidemia , hypertension , thrombotic event cardiac disease . For female childbearing potential , negative pregnancy test must document prior randomization . Female male patient fertile must agree use effective form contraception sexual partner randomization 4 month end treatment . informed consent sign , accord national regulation Lymphoid blast crisis CML , WHO performance status ≤ 50 % ( Karnofsky ) ≥ 3 ( ECOG ) . Active HBV HCV hepatitis , AST/ALT ≥ 2.5 x ULN bilirubin ≥ 1.5 x ULN . History acute pancreatitis within 1 year study history chronic pancreatitis . History alcohol abuse . Ongoing active infection . Uncontrolled hypertriglyceridemia ( triglyceride &gt; 450 mg/dL ) . Clinically significant , uncontrolled active cardiovascular disease , specifically include , restrict : Any history myocardial infarction , stroke , revascularization , Unstable angina transient ischemic attack within 6 month prior enrollment Congestive heart failure within 6 month prior enrollment , leave ventricular ejection fraction ( LVEF ) less low limit normal per local institutional standard History clinically significant ( determined treat physician ) atrial arrhythmia Any history ventricular arrhythmia Any history venous thromboembolism include deep venous thrombosis pulmonary embolism . Uncontrolled hypertension ( diastolic blood pressure &gt; 90 mm Hg ; systolic &gt; 140 mm Hg ) . Patients hypertension treatment study entry effect blood pressure control . Taking medication know associated torsades de pointes . Taking medication herbal supplement know strong inhibitor CYP3A4 within least 14 day first dose ponatinib . Creatinine level &gt; 2.5mg/dl glomerular filtration rate ( GFR ) &lt; 20 ml/min proteinuria &gt; 3.5 g/day . Gastrointestinal ( GI ) function impairment , GI disease may significantly alter absorption study drug . Patients currently receive treatment medication potential prolong QT interval ( list Appendix 4 ) medication either discontinue switched different medication prior start study drug . Patients receive investigational drug ≤ 4 week . Patients undergone major surgery ≤ 2 week prior start study drug recover side effect therapy . Patients pregnant breast feed adult reproductive potential employ effective method birth control ( woman childbearing potential must negative serum pregnancy test within 48 hr . prior administration Ponatinib ) . Postmenopausal woman must amenorrheic least 12 month consider nonchildbearing potential . Male female patient must agree employ effective barrier method birth control throughout study 4 month follow discontinuation study drug . Patients history another primary malignancy currently clinically significant currently require active intervention . Patients unwilling unable comply protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>